Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rho GTPase activating protein 27 pseudogene 2 (ARHGAP27P2) is classified as a pseudogene, meaning it is a nonfunctional DNA segment that resembles the functional ARHGAP27 gene but does not encode an active protein product in humans[3][7][8][9][10]. Pseudogenes like ARHGAP27P2 arise through gene duplication or retrotransposition events and typically contain significant mutations or disruptions (such as frameshifts or premature stop codons) that prevent production of a functional protein[10]. As such, ARHGAP27P2 is not a therapeutic or biological target (such as a receptor or enzyme) and does not possess described molecular function, associated disease roles, or drug interactions. It serves primarily as a genomic relic with no known physiological or pathological function in humans[9][10].\n\nKey clarification:\nAlthough the closely related ARHGAP27 gene encodes an active member of the Rho GTPase activating protein family involved in cytoskeletal regulation and is implicated in several diseases, ARHGAP27P2 is a distinct, nonfunctional pseudogene and does not have the same functional or therapeutic relevance[1][3][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rho GTPase activating protein 27 pseudogene 2 (ARHGAP27P2).